NASDAQ:AKCA - Akcea Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$26.10 +0.02 (+0.08 %)
(As of 11/13/2018 01:48 PM ET)
Previous Close$26.08
Today's Range$25.51 - $26.6547
52-Week Range$15.23 - $40.75
Volume222,247 shs
Average Volume414,807 shs
Market Capitalization$2.27 billion
P/E Ratio-11.65
Dividend YieldN/A
Beta2.57
Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG; and Accredo specialty pharmacy to distribute TEGSEDI, a subcutaneous injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKCA
Previous Symbol
CUSIPN/A
Phone617-207-0202

Debt

Debt-to-Equity RatioN/A
Current Ratio3.64
Quick Ratio3.64

Price-To-Earnings

Trailing P/E Ratio-11.65
Forward P/E Ratio-9.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$55.21 million
Price / Sales42.17
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book9.67

Profitability

EPS (Most Recent Fiscal Year)($2.24)
Net Income$-109,750,000.00
Net Margins-245.68%
Return on Equity-77.03%
Return on Assets-53.39%

Miscellaneous

Employees100
Outstanding Shares89,210,000
Market Cap$2.27 billion
OptionableOptionable

Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its earnings results on Monday, November, 5th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.07. The firm earned $19.24 million during the quarter, compared to the consensus estimate of $20.52 million. Akcea Therapeutics had a negative net margin of 245.68% and a negative return on equity of 77.03%. The firm's revenue for the quarter was up 94.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.33) EPS. View Akcea Therapeutics' Earnings History.

What price target have analysts set for AKCA?

6 equities research analysts have issued 12 month price targets for Akcea Therapeutics' stock. Their predictions range from $31.00 to $46.00. On average, they anticipate Akcea Therapeutics' stock price to reach $40.50 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

What is the consensus analysts' recommendation for Akcea Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

Has Akcea Therapeutics been receiving favorable news coverage?

News stories about AKCA stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a news sentiment score of 2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Akcea Therapeutics' key competitors?

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the folowing people:
  • Ms. Paula Soteropoulos, CEO & Director (Age 50)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 52)
  • Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer, Exec. VP & Head of Regulatory Affairs (Age 67)
  • Ms. Sarah Boyce, Pres & Director (Age 46)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 45)

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Who are Akcea Therapeutics' major shareholders?

Akcea Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), BB Biotech AG (2.68%), BlackRock Inc. (2.21%), Bellevue Group AG (0.47%), Alps Advisors Inc. (0.18%) and PNC Financial Services Group Inc. (0.06%). View Institutional Ownership Trends for Akcea Therapeutics.

Which major investors are selling Akcea Therapeutics stock?

AKCA stock was sold by a variety of institutional investors in the last quarter, including BB Biotech AG, Alliancebernstein L.P., Wells Fargo & Company MN, BlackRock Inc., Bank of New York Mellon Corp and Credit Suisse AG. View Insider Buying and Selling for Akcea Therapeutics.

Which major investors are buying Akcea Therapeutics stock?

AKCA stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, PNC Financial Services Group Inc., Bellevue Group AG and Alps Advisors Inc.. View Insider Buying and Selling for Akcea Therapeutics.

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $26.10.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $2.27 billion and generates $55.21 million in revenue each year. The company earns $-109,750,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. Akcea Therapeutics employs 100 workers across the globe.

What is Akcea Therapeutics' official website?

The official website for Akcea Therapeutics is http://www.akceatx.com.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]


MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  412
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel